CARDIOTEC Drug Patent Profile

Which patents cover Cardiotec, and when can generic versions of Cardiotec launch?

Cardiotec is a drug marketed by Bracco and is included in one NDA.

The generic ingredient in CARDIOTEC is technetium tc-99m teboroxime kit. There is one drug master file entry for this compound. Additional details are available on the technetium tc-99m teboroxime kit profile page.

Summary for CARDIOTEC

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	CARDIOTEC at DailyMed

US Patents and Regulatory Information for CARDIOTEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	CARDIOTEC	technetium tc-99m teboroxime kit	INJECTABLE;INJECTION	019928-001	Dec 19, 1990		DISCN	No	No

Expired US Patents for CARDIOTEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bracco	CARDIOTEC	technetium tc-99m teboroxime kit	INJECTABLE;INJECTION	019928-001	Dec 19, 1990
Bracco	CARDIOTEC	technetium tc-99m teboroxime kit	INJECTABLE;INJECTION	019928-001	Dec 19, 1990

International Patents for CARDIOTEC

See the table below for patents covering CARDIOTEC around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	48429
Australia	5492786
Australia	583101
Canada	1257288	ACIDE BORONIQUE EMPLOYE COMME PRODUIT D'ADDITION DE COMPLEXES DE TECHNETIUM-99M ET DE DIOXIME (BORONIC ACID ADDUCTS OF TECHNETIUM-99M DIOXIME COMPLEXES)
Germany	3667290
Denmark	168920

Supplementary Protection Certificates for CARDIOTEC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119

Cardiotec (CARDIOTEC) Market Dynamics and Financial Trajectory: Pricing, Demand Drivers, Competitive Threats, and Exclusivity Timeline

Last updated: June 20, 2026

No usable, source-backed market or financial data is available for the specific product name CARDIOTEC (including confirmed active ingredient, dosage form, manufacturer, therapeutic indication, FDA status, pricing, or revenue). Without verified drug identity and corresponding financial disclosures, an accurate market-dynamics and financial-trajectory analysis cannot be produced.

What is CARDIOTEC’s active ingredient, indication, and FDA status?

Featured snippet: Unable to verify product identity or FDA status for “CARDIOTEC.”

Which company markets CARDIOTEC and what label does it have?

Featured snippet: Not determinable from the available information.

Is CARDIOTEC listed in the Orange Book or FDA drug databases?

Featured snippet: Not determinable.

What drives CARDIOTEC demand in the US market?

Featured snippet: Not determinable without confirmed indication and formulation.

Hospital vs outpatient utilization

Featured snippet: Not determinable.

Clinical adoption factors

Featured snippet: Not determinable.

Reimbursement and payer coverage

Featured snippet: Not determinable.

How has CARDIOTEC pricing moved over time?

Featured snippet: Not determinable.

WAC vs net price vs AMP trends

Featured snippet: Not determinable.

340B, Medicaid, and Medicare Part D effects

Featured snippet: Not determinable.

What is the financial trajectory of CARDIOTEC (revenue, margins, and growth rates)?

Featured snippet: Not determinable from the available information.

Company segment exposure

Featured snippet: Not determinable.

Quarterly sales inflections (launch, formulation switch, supply events)

Featured snippet: Not determinable.

Guidance and analyst estimate trends

Featured snippet: Not determinable.

When does CARDIOTEC lose exclusivity, and what does that do to sales?

Featured snippet: Not determinable without confirmed FDA reference product and patent/originator identity.

What patents protect CARDIOTEC, and when do they expire?

Featured snippet: Not determinable.

When does patent “B” and “C” exclusivity end?

Featured snippet: Not determinable.

How many listed Orange Book patents cover the marketed dosage forms?

Featured snippet: Not determinable.

What generic entry risks exist for CARDIOTEC?

Featured snippet: Not determinable.

Paragraph IV challenges and settlement probability

Featured snippet: Not determinable.

First generic timeline and launch sequencing

Featured snippet: Not determinable.

Authorized generic risk

Featured snippet: Not determinable.

How does CARDIOTEC compare with competing drugs in the same therapeutic class?

Featured snippet: Not determinable without indication and comparators.

Competitor list and market share map

Featured snippet: Not determinable.

Formulation and convenience advantages

Featured snippet: Not determinable.

Clinical guideline positioning

Featured snippet: Not determinable.

What FDA/regulatory milestones affect CARDIOTEC’s commercial outlook?

Featured snippet: Not determinable.

NDA/BLA pathway and exclusivity basis

Featured snippet: Not determinable.

Label changes, REMS, and safety communications

Featured snippet: Not determinable.

What patent litigation affects CARDIOTEC’s launch and revenue stability?

Featured snippet: Not determinable without confirmed patent estate and parties.

Who sued whom, and what was the procedural posture?

Featured snippet: Not determinable.

Settlement terms that shift generic timing

Featured snippet: Not determinable.

What commercial outcomes have generics already produced in similar products?

Featured snippet: Not determinable without confirmed reference product and class.

Price erosion curves after first ANDA

Featured snippet: Not determinable.

Formulary displacement and budget impact

Featured snippet: Not determinable.

Key Takeaways

No source-backed, product-specific market, pricing, or revenue trajectory can be produced for “CARDIOTEC” without verified drug identity, FDA status, and financial disclosures.

FAQs

1. Is CARDIOTEC considered a branded or generic drug in the US?
2. What is the most likely biosimilar or generic substitution risk for CARDIOTEC?
3. How do payer rules typically impact CARDIOTEC net pricing in high-utilization settings?
4. What are the common drivers of volume growth for drugs like CARDIOTEC in cardiology categories?
5. What timing does patent expiration usually create for the first generic launch in the same class?

References (APA)

1. (No citable sources were used because CARDIOTEC could not be verified to a specific drug identity and dataset.)